Uremic Pruritus (UP) in Dialysis - Management

Prurigo nodularis - a severe sequela of untreated uremic pruritus (Comprehensive Clinical Nephrology, 7th Ed.)

Pathogenesis (Brief)

• Opioid imbalance - overexpression of mu-opioid receptors with relative underexpression of kappa receptors in dermal cells and lymphocytes
• Immune/inflammatory - elevated IL-2, IL-6, IL-31, CRP; Th1 cell predominance (reversed by UVB)
• Mast cell activation - increased dermal mast cells; histamine/tryptase release triggered by substance P
• Xerosis - atrophy of sweat and sebaceous glands; present in 60-90% of dialysis patients; directly predisposes to itch
• Divalent ions / hyperparathyroidism - elevated calcium-phosphate product contributes (but no consistent linear correlation)
• Inadequate dialysis and uremic toxin accumulation
• Dialysis-specific triggers - allergic reactions to heparin, ethylene oxide (ETO), formaldehyde, acetate, or the dialysis membrane itself

Step 1: Rule Out and Treat Other Causes

• Primary skin disorders (urticaria, psoriasis, atopic/contact dermatitis)
• Hepatic disease (hepatitis C is common in dialysis patients)
• Endocrine causes (hypothyroidism, diabetes)
• Drug reactions

Step 2: Dialysis Optimization

Step 3: Skin Care (Topical / First-Line)

• Simple, fragrance-free emollients applied after dialysis
• Bath oil therapy with polidocanol (monoether of lauryl alcohol + macrogol) helps some patients
• Sericin cream (biopolymer from silkworm) - reduced UP in a double-blind placebo-controlled trial of 50 patients over 6 weeks
• Pramoxine-based anti-itch lotion - superior to control lotion in hemodialysis patients

Step 4: Systemic Pharmacological Treatment

A. Antihistamines

• Classic H1 antihistamines have efficacy similar to emollients (modest at best) - histamine plays a partial role only
• Second-generation agents (e.g., desloratadine) may have some effect
• Ketotifen 2-4 mg/day (mast cell stabilizer): beneficial in one small study

B. Gabapentinoids (Well-Supported)

• Gabapentin 100-300 mg given after each dialysis session (thrice weekly): significantly reduces UP score in two controlled studies at 4 weeks
• Must reduce dose in ESKD - narrow therapeutic window, risk of accumulation causing neurotoxicity
• Common side effects: dizziness, somnolence, fatigue, nausea
• Pregabalin shows similar effects in smaller studies
• Gabapentin was superior to both ondansetron and doxepin in randomized trials

C. Kappa-Opioid Receptor Agonists (Targeted Therapy - Major Advance)

• Nalfurafine (IV, after HD): reduced itching intensity, excoriations, and sleep disturbances in two RCTs (n=144). Oral 2.5-5 mg equally effective over 2 weeks in 337 patients. 1-year study confirmed sustained benefit; side effects include insomnia (19%), constipation (7%), elevated prolactin
• Difelikefalin (IV, thrice weekly): peripherally restricted selective kappa-opioid receptor agonist, now FDA-approved for moderate-to-severe CKD-aP in hemodialysis adults. In a 12-week RCT, 51.9% of patients responded vs 30.9% placebo. Quality of life improved. Side effects: diarrhea, dizziness, vomiting. Should be considered whenever available - Comprehensive Clinical Nephrology, 7th Ed.

D. 5-HT3 Antagonists

• Ondansetron: effective in one small peritoneal dialysis study, but a larger RCT in hemodialysis patients failed to show superiority over placebo - not recommended as a standalone treatment

E. SSRIs

• Sertraline and other SSRIs feature in the sequential management algorithm as a later option, particularly for patients with co-existing depression and UP

F. Immunomodulators / Immunosuppressive Agents (Reserved for Refractory Cases)

• Thalidomide (7-day course): reduced UP intensity by up to 80% in a placebo-controlled crossover study (n=29 HD patients). Reserved for therapy-resistant severe UP in non-reproductive-age patients. Risks: teratogenicity, peripheral neuropathy, cardiovascular side effects
• Tacrolimus 0.1% ointment (topical): a prospective study of 25 patients showed significant UP reduction after 6 weeks. Well tolerated, no detectable systemic exposure. However, a smaller vehicle-controlled trial showed equal benefit from vehicle alone; long-term risks unknown

Step 5: Phototherapy

• Narrowband UVB (280-315 nm): effective and well-tolerated for UP
• Protocol: thrice-weekly total body sessions, 8-10 sessions total
• Duration of effect: variable, may last several months
• Mechanism: shifts Th1 to Th2 immune balance, reduces IL-31 and inflammatory signaling
• Contraindicated for prolonged use (>12 weeks) in fair-skinned patients (phototypes I and II) due to carcinogenic risk

Management Algorithm (Sequential Approach)

Exclude secondary causes
       ↓
Optimize dialysis + mineral metabolism
       ↓
Emollients / topical therapy
       ↓
Antihistamines (second-generation)
       ↓
Gabapentin (post-dialysis, 100-300 mg TIW)
       ↓
Phototherapy (UVB)
       ↓
Kappa-opioid agonist (nalfurafine / difelikefalin)
       ↓
SSRI
       ↓
Thalidomide / tacrolimus ointment (refractory only)

Special Note: Intra-dialytic Allergic Pruritus

• Suspected triggers: heparin, ETO, formaldehyde, acetate dialysate, dialysis membrane
• Management: switch to gamma-ray sterilized dialyzers, eliminate formaldehyde, switch to bicarbonate dialysate, use low-calcium/magnesium dialysate, consider alternative anticoagulants
• Also consider reactions to antiseptic solutions, rubber gloves, needle components, or adhesive tape used at the access site

Recent Evidence (2026 Systematic Review)

• Comprehensive Clinical Nephrology, 7th Ed., Chapter 91 (Cutaneous Disorders in CKD) and Chapter on Hemodialysis Complications
• Fitzpatrick's Dermatology, related sections on acquired perforating dermatosis and uremic skin
• Dragos F et al. (2026). CKD-aP systematic review. Int J Mol Sci, 27(2):851